If you are worried about getting a diagnosis of dementia, support somone with dementia, work in the field, or have been diagnosed with dementia, you will have seen the recent news on June 7, about the drug that the US Food and Drug Administration ushered in as a revolution for treating Alzheimer’s disease: approving aducanumab (marketed as Aduhelm). I am one of a few who is not excited or even happy about it, and I do not support the release of this drug.
It feels to me, like people with dementia are being used as pharmaceutical guinea pigs…
There are others who are not positive of the release of this new drug either, such as Dr Jason Karlawish, who wrote an Opinion piece in the Philadelphia Inquirer, We can’t drug our way out of despair over Alzheimer’s.
“We need to break the absurdity of embracing a pharmaceutical stimulus package for care.”Jason Karlawish
In the article, he says, The drug reduces levels of brain amyloid. It’s uncertain whether this slows progressive disability. The FDA is requiring Biogen to demonstrate if the drug can deliver what matters to patients and their caregivers. That study hasn’t begun. Meanwhile, Biogen can sell the drug to those willing to take on its risks and uncertainties at an estimated annual per-patient cost of nearly $60,000.
We need to break the absurdity of embracing a pharmaceutical stimulus package for care. We need a new approach to Alzheimer’s and all other diseases that cause dementia. We do need effective drug treatments. But short of cures, patients need services and supports.
So just like BPSD which was thrust upon the sector without sufficient evidence based research to prove its validity… it continues to be the case with dementia, where we still do not need the same level of evidence based research to move ahead with treatments of any kind. Shockingly, I’ve even had a few medical doctors and researchers say to me, what does it matter if we get it wrong, people with dementia won’t know. Shame on them, and shame on those who have thrust this drug onto us, without adequate due diligence.
So, if you want to learn more about managing dementia including MCI in a more holistic way, and in a way that does not put people with dementia at risk or anything other than improving their quality of life and well-being, and one that may even slow down or reverse their cognitive disaiblities, then you should register now for these two free DAI webinars.
WEBINAR 1: HOW TO MAKE DEMENTIA A RARE DISEASE!
Professor Bredesen’s talk will describe the first reversals of cognitive decline in patients with Alzheimer’s disease and a recent successful clinical trial. A great number of DAI members have also believed that a lifestyle approach, to a diagnosis of dementia is closest we have to hope, and even if not a cure, it will improve our quality of life. This is also the reason DAI started its Brain Health Hub and twice monthly meetings many years ago.
Dale Bredesen, M.D., is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease and other dementias, and the author of the New York Times bestsellers The End of Alzheimer’s, The End of Alzheimer’s Program, and the newly released The First Survivors of Alzheimer’s.
This discussion style presentation will primarily be about the latest findings in Precision Medicine & Protocols for MCI & Dementia. Dr Nate Bergman is absolutely convinced that Alzheimer’s and other brain diseases are generally treatable and reversible. Early translational evidence is supports this belief.
Dr Nate Bergman DO, has been passionate about proactive, preventive, and participatory medicine since his days as a research fellow at the NIH. He completed a fellowship in geriatric medicine at the Cleveland Clinic with emphasis on the aging brain and body. Prior to his current position at Kemper Cognitive Wellness, he co-developed the Cleveland Clinic Center for Functional Medicine’s program for cognitive impairment.